This grant application is submitted in response to RFA AI-94-029, """"""""Pediatric AIDS: Factors in Transmission and Pathogenesis"""""""". Study of early events in HIV infection after perinatal virus exposure of infants is especially needed for the rational design of prophylactic treatments or vaccines to prevent HIV infection by perinatal exposure as well as to develop anti-viral therapies for infected infants. Such human studies are difficult or impossible to perform because the infecting viral inocula, the route of exposure to virus, and the precise time of infection are unknown. However, the SIV/rhesus macaque model of pediatric HIV infection is ideally suited to study early events in perinatal transmission of virus because virological and host variables can be experimentally separated to test specific hypotheses. Three pieces of critical information are lacking in human studies of perinatal HIV transmission that can be easily obtained in the SIV/rhesus macaque model of HIV perinatal transmission: (1) detailed understanding of the role of viral characteristics in the infecting inoculum including the infectious titer and biological properties of viral variants, (2) timing and route of exposure to virus, and (3) the roles of immune responses and virus load on pathogenesis by detailed measures of virus levels and cell- mediated and humoral immunity, in infected neonates. Hypotheses: 1) The rate of disease progression in SIV-infected neonates is determined by the infectious dose and composition (genotype and phenotype) of the virus inoculum and the route of virus exposure, and 2) Therapies or treatments that reduce the dose of infectious virus below a minimum threshold associated with persistent viremia will delay or prevent fatal disease in SIV-infected neonatal rhesus macaques.
Three Specific Aims are proposed: 1) To determine the minimum dose of SIV that results in rapidly fatal immunodeficiency following oral and intravenous virus exposures. 2) To determine whether disease progression, immune responses or virus load differs in rhesus neonates infected with defined mixtures of pathogenic and attenuated SIV variants. 3) To prevent virus infection or disease in SIV-inoculated neonatal rhesus macaques using a topical antiviral agent or immunotherapies. The project proposed will attempt to answer fundamental questions regarding the effects of different viral variants, infectious doses of virus, and routes of virus exposure on the rate of disease progression in neonates after exposure to SIV and, by extension, HIV. The information generated by this project will be directly applicable to the design of strategies aimed at preventing HIV infection of human infants or delaying disease progression in those infants that become HIV-infected.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI039109-05
Application #
2887114
Study Section
Special Emphasis Panel (SRC (64))
Program Officer
Hoff, Rodney
Project Start
1995-09-30
Project End
2001-08-31
Budget Start
1999-09-01
Budget End
2001-08-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Other Domestic Higher Education
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Greenier, Jennifer L; Van Rompay, Koen K A; Montefiori, David et al. (2005) Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously Virol J 2:11
Van Rompay, Koen K A; Abel, Kristina; Lawson, Jonathan R et al. (2005) Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 38:124-34
Van Rompay, Koen K A; Greenier, Jennifer L; Cole, Kelly Stefano et al. (2003) Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 77:179-90
Abel, Kristina; Alegria-Hartman, Michelle J; Rothaeusler, Kristina et al. (2002) The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J Virol 76:8433-45
Marthas, M L; Lu, D; Penedo, M C et al. (2001) Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses 17:1455-66
Greenier, J L; Miller, C J; Lu, D et al. (2001) Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol 75:3753-65
Abel, K; Alegria-Hartman, M J; Zanotto, K et al. (2001) Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques. Cytokine 16:191-204
van Rompay, K K; Dailey, P J; Tarara, R P et al. (1999) Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. J Virol 73:2947-55
Van Rompay, K K; Berardi, C J; Dillard-Telm, S et al. (1998) Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 177:1247-59
Miller, C J; Marthas, M; Greenier, J et al. (1998) In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J Virol 72:3248-58